Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sandner

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
Expert Opinion on Therapeutic Patents|January 4, 2021
Soluble guanylate cyclase stimulators and their potential use: a patent reviewPeter Sandner, Alexandros Vakalopoulos, Michael G Hahn, et al.
Biochemical Pharmacology|January 6, 2025
Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activationTheresa Wittrien, Anne Rühle, Christin Elgert, et al.
European Journal of Pharmacology|December 7, 2024
Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?Olga Gawrys, Petr Kala, Janusz Sadowski, et al.
International Journal of Molecular Sciences|June 13, 2018
The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical PerspectiveShalini M Krishnan, Jan R Kraehling, Frank Eitner, et al.
Biochemical Pharmacology|September 23, 2025
Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failureOlga Gawrys, Petr Kala, Michal Šnorek, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|March 20, 2024
The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclaseRaymond L Benza, Ekkehard Grünig, Peter Sandner, et al.
Circulation. Heart Failure|December 6, 2021
Vericiguat Improves Aortic Wave Reflection Parameters in a New Preclinical Model of HypertensionKatharina Boden, Peter Sandner, Lothar Roessig, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|June 16, 2009
Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypassGábor Szabó, Tamás Radovits, Gábor Veres, et al.
British Journal of Pharmacology|August 20, 2019
Mind the gap (junction): cGMP induced by nitric oxide in cardiac myocytes originates from cardiac fibroblastsLukas Menges, Christian Krawutschke, Ernst-Martin Füchtbauer, et al.
European Urology|November 2, 2010
Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured ratsDelphine Behr-Roussel, Stephanie Oger, Stéphanie Caisey, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
Expert Opinion on Therapeutic Patents|January 4, 2021
Soluble guanylate cyclase stimulators and their potential use: a patent reviewPeter Sandner, Alexandros Vakalopoulos, Michael G Hahn, et al.
Biochemical Pharmacology|January 6, 2025
Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activationTheresa Wittrien, Anne Rühle, Christin Elgert, et al.
European Journal of Pharmacology|December 7, 2024
Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?Olga Gawrys, Petr Kala, Janusz Sadowski, et al.
International Journal of Molecular Sciences|June 13, 2018
The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical PerspectiveShalini M Krishnan, Jan R Kraehling, Frank Eitner, et al.
Biochemical Pharmacology|September 23, 2025
Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failureOlga Gawrys, Petr Kala, Michal Šnorek, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|March 20, 2024
The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclaseRaymond L Benza, Ekkehard Grünig, Peter Sandner, et al.
Circulation. Heart Failure|December 6, 2021
Vericiguat Improves Aortic Wave Reflection Parameters in a New Preclinical Model of HypertensionKatharina Boden, Peter Sandner, Lothar Roessig, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|June 16, 2009
Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypassGábor Szabó, Tamás Radovits, Gábor Veres, et al.
British Journal of Pharmacology|August 20, 2019
Mind the gap (junction): cGMP induced by nitric oxide in cardiac myocytes originates from cardiac fibroblastsLukas Menges, Christian Krawutschke, Ernst-Martin Füchtbauer, et al.
European Urology|November 2, 2010
Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured ratsDelphine Behr-Roussel, Stephanie Oger, Stéphanie Caisey, et al.
Pageof 11